Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korean Dong-A In Talks With Warner Chilcott For Additional Indications For ED Drug Zydena

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Dong-A Pharmaceutical says its U.S. partner Warner Chilcott is seeking an expanded indication of lower urinary track symptoms for its erectile dysfunction drug Zydena (udenafil)

You may also be interested in...



Struggling From Price Cuts, Korea’s Dong-A Looks To Change Course

Korea’s top pharma company saw flat sales and a drop in profits in the third quarter, showing the impact of industry-wide price cuts. GSK holds a 10% stake in Dong-A.

Pfizer's Viagra Challenged As Korea's JW Choongwae Launches ED Product In Korea

SEOUL - South Korea's JW Choongwae Pharmaceutical Corp. launched its new erectile dysfunction product Zepeed (avanafil) in Korea Oct. 19, ahead of approval in the U.S

Pfizer's Viagra Challenged As Korea's JW Choongwae Launches ED Product In Korea

SEOUL - South Korea's JW Choongwae Pharmaceutical Corp. launched its new erectile dysfunction product Zepeed (avanafil) in Korea Oct. 19, ahead of approval in the U.S

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel